|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1800 CONCORD PIKE, P.O. BOX 15437 |
Address2 |
|
City | WILMINGTON |
State | DE |
Zip Code | 19850-5437 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 54073-12
|
||||||||
|
6. House ID# 349750000
|
TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Sarah Arbes |
Date | 7/21/2025 4:16:04 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
HR 1, One Big Beautiful Bill Act
HR 946/S 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act
HR 1262/ S 932, Give Kids A Chance Act
HR 1503/S 2916, Prescription Information Modernization Act
Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language); consideration of small molecule drugs, biologics, and genetically targeted technologies; duplicate discounts as required by IRA; Policies related to the definition of a qualifying single source drug under the IRA; Issues related to the IRA definition of a drug for purposes of price negotiation selection; Issues related to expanding/amending the orphan drug exclusion in IRA
Orphan drugs and diseases
Education to Hill staff on next generation propellant and PFAS
Issues related to pharmacy benefit manager (PBM) reform; Policies related to 340B rebate model for IRA compliance;
Reforms to the 340B program; Issues related to mitigation of 340B
Issues related to the price and manufacture of inhaled medicines
Issues related to drug pricing
Issues related to the US manufacturing of pharmaceuticals
Issues related to importation of drugs
Issues related to direct-to-consumer drug delivery policy options
Policies related to international reference pricing for pharmaceuticals
Issues related to environmental sustainability
Company sustainability policy issues
FDA modernization policy issues
Issues related to FDA Orange Book patent listings
Pediatric rare disease priority review voucher
Reauthorization of the pediatric priority review voucher program
General issues related to health equity in rare disease and clinical trials
General issues related to vaccine safety, efficacy, and access
General issues related to rare disease and orphan drugs
General issues related to ACIP recommendations
Tariffs/trade policies related to tariffs on pharmaceuticals
Most favored nation policies related to pharmaceuticals
Issues related to a Most Favored Nations policy in Medicare and Medicaid
Issues related to the Medicare title in the One Big Beautiful Bill Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), White House Office, Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katie |
Jones |
|
|
|
Sarah |
Arbes |
|
|
|
Caroline |
Quat |
|
|
|
Art |
Motta |
|
|
|
Lisa |
Langenderfer |
|
|
|
Emily |
Mace |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Centers for Medicare and Medicaid Innovation (CMMI) policy issues
Value-based payment arrangements
Medicare drug price negotiation
Policies related to the use of international reference pricing in Medicare/Medicaid
Most Favored Nation drug pricing proposals
Issues related to e-labeling and allowing FDA to finalize a rule to allow digital versions of prescriptions
Medicare patient access to rare disease therapies Part B and Part D drugs
Medicare Part D reform and inflation penalties
Medicare patient access to cancer screening
Medicaid Drug Rebate Program proposed rule
Definition of Qualified Single Source Drug (QSSD) for purposes of Medicare drug price negotiation
E-labeling - allowing FDA to finalize a rule to allow digital versions of prescriptions
Issues related to the digital communication of prescribing information for drugs
Efforts to improve coding, coverage, and access for rare disease therapies
General issues related to diagnostic reimbursement
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katie |
Jones |
|
|
|
Caroline |
Quat |
|
|
|
Art |
Motta |
|
|
|
Lisa |
Langenderfer |
|
|
|
Emily |
Mace |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
E-labeling (allowing health care providers to receive prescribing information for drugs electronically rather than in paper form from manufacturers)
Issues related to increasing production of US manufacturing
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katie |
Jones |
|
|
|
Caroline |
Quat |
|
|
|
Art |
Motta |
|
|
|
Lisa |
Langenderfer |
|
|
|
Emily |
Mace |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
HR 591 - Defending American Jobs and Investment Act
HR 1414 - Camerons Law, to restore orphan drug research tax credit
HR 1990 - American Innovation and R&D Competitiveness Act of 2025
HR 2423 - Unfair Tax Prevention Act
S 1605 - International Competition for American Jobs Act
Expiring provisions of the Tax Cut and Jobs Act law - deduction of research and development expenditures
Tax reform in budget reconciliation and Byrd rules
Issues related to proposed Sec. 899
Issues related to international tax rules (GILTI/FDII/BEAT)
Tariffs (general education, country-specific tariffs, sector-specific tariffs)
Issues related to the renewable energy tax credits and other energy credits included in the Inflation Reduction Act
Education on tax in preparation for 2025 tax legislation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katie |
Jones |
|
|
|
Caroline |
Quat |
|
|
|
Art |
Motta |
|
|
|
Lisa |
Langenderfer |
|
|
|
Emily |
Mace |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Issues related to patents and intellectual property
Issues related to FDA Orange Book patent listings
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Quat |
|
|
|
Art |
Motta |
|
|
|
Katie |
Jones |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAR
16. Specific lobbying issues
S.998 - Medical Supply Chain Resiliency Act
Trade and tariffs (general education, country-specific tariffs, sector-specific tariffs)
Pharmaceutical manufacturing (general education)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katie |
Jones |
|
|
|
Art |
Motta |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |